U.S. Markets open in 8 hrs 49 mins

Sarepta Therapeutics, Inc. (SRPT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
83.19+1.00 (+1.22%)
At close: 04:00PM EST
83.95 +0.76 (+0.91%)
After hours: 05:16PM EST

Sarepta Therapeutics, Inc.

215 First Street
Suite 415
Cambridge, MA 02142
United States
617 274 4000

Full Time Employees866

Key Executives

NameTitlePayExercisedYear Born
Mr. Douglas S. IngramPres, CEO & Director1.29MN/A1963
Mr. Ian Michael EstepanExec. VP & CFO684.12kN/A1976
Mr. William F. CiambroneExec. VP of Technical Operations679.94kN/A1964
Dr. Louise Rodino-Klapac Ph.D.Exec. VP & Chief Scientific Officer739.05kN/A1978
Dr. Gilmore O'Neill M.D.Exec. VP of R&D and Chief Medical Officer891.94kN/A1965
Mr. Joseph BraticaController & VP438.51k2.07M1964
Mary JenkinsSr. Mang. of Investor RelationsN/AN/AN/A
Mr. Ryan E. BrownSr. VP, Gen. Counsel & Corp. Sec.N/AN/A1978
Dr. Diane L. BerrySr. VP of Global Health Policy and Gov. & Patient AffairsN/AN/AN/A
Mr. Dallan MurraySr. VP & Chief Commercial OfficerN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. It also has a research and option agreement with Codiak BioSciences, Inc. to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing, and RNA technologies for neuromuscular diseases; and research collaboration with Genevant Sciences for lipid nanoparticle-based gene editing therapeutics. Sarepta Therapeutics, Inc. was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Sarepta Therapeutics, Inc.’s ISS Governance QualityScore as of June 1, 2021 is 3. The pillar scores are Audit: 3; Board: 2; Shareholder Rights: 3; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.